CCT3833

CCT3833 is an orally administered small molecule inhibitor that targets both the RAF family of serine/threonine protein kinases and SRC family tyrosine kinases. It was developed to address cancers driven by mutations in the KRAS gene, which are common in pancreatic ductal adenocarcinoma, colorectal cancer, non-small cell lung cancer (NSCLC), and melanoma. By inhibiting both RAF and SRC pathways simultaneously, CCT3833 aims to overcome resistance mechanisms that limit the effectiveness of single-pathway inhibitors. Preclinical studies demonstrated significant efficacy in KRAS-mutant tumor models—including colorectal, lung, and pancreatic xenografts—where it outperformed single-agent panRAF or SRC inhibitors. In early clinical evaluation (Phase 1), CCT3833 showed promising activity including prolonged progression-free survival in a patient with KRAS-mutant spindle cell sarcoma who had failed prior therapies[1][4][5][8].

Other names

BAL-3833BAL3833BAL 3833